Literature DB >> 12010215

Effects of post-mortem delay and storage duration on the expression of GFAP in normal human adult retinae.

Kathy H C Wu1, Philip L Penfold, Francis A Billson.   

Abstract

Glial fibrillary acidic protein (GFAP) is an established marker of retinal glia and has been shown to be modulated by several cytokines and retinal pathology. The influence of a number of factors, including post-mortem delay, storage duration and retinal pathology, on the distribution and morphology of macroglia and GFAP antigenicity was examined in human retina. The effects of these parameters on GFAP expression were estimated using immunohistochemistry, confocal microscopy and image analysis. Changes in expression of antigenicity were analysed in human retinal cryosections at three levels: constitutive,aberrant and total. The results indicated that short-term and long-term storage duration had no significant effect on GFAP immunoreactivity at all three levels of expression (P > 0.2).However, a significant increase in GFAP immunoreactivity and distribution at all three levels of expression was associated with prolonged post-mortem delay (> 30 h) (P < 0.05). This study highlights the importance of rigorous matching of post-mortem delay between control specimens in histological studies of human retinae. The study further demonstrates the utility of Eye Bank retinae fixed and stored in 2% paraformaldehyde, provided that appropriate controls are applied.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12010215     DOI: 10.1046/j.1442-9071.2002.00515.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  2 in total

1.  Complement-associated deposits in the human retina.

Authors:  Aditya Seth; Jing Cui; Eleanor To; Melissa Kwee; Joanne Matsubara
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-02       Impact factor: 4.799

2.  Differential expression of GFAP in early v late AMD: a quantitative analysis.

Authors:  K H C Wu; M C Madigan; F A Billson; P L Penfold
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.